This HTML5 document contains 81 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n26http://linked.opendata.cz/resource/drugbank/drug/DB01014/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/mesh/concept/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01014/identifier/drugbank/
n18http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB01014/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01014/identifier/chebi/
n15http://www.drugs.com/cdi/
n8http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01014/identifier/wikipedia/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01014
rdf:type
n3:Drug
n3:description
Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
n3:dosage
n21:271B51D0-363D-11E5-9242-09173F13E4C5 n21:271B51D1-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19743890 # Ragunath K, Williams JG: Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001 Oct;15(10):1549-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11563993
n3:group
investigational approved
n3:halfLife
Half-life could not be determined.
n3:indication
For the treatment of mildly to moderately active ulcerative colitis.
n3:manufacturer
n10:271B51CC-363D-11E5-9242-09173F13E4C5 n10:271B51CD-363D-11E5-9242-09173F13E4C5 n10:271B51CA-363D-11E5-9242-09173F13E4C5 n10:271B51CB-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB01014 n18:DB01014
dcterms:title
Balsalazide
adms:identifier
n20:267413 n22:DB01014 n23:Balsalazide n24:65649-101-02 n26:PA448536
n3:mechanismOfAction
The mechanism of action of 5-aminosalicylic acid is unknown, but appears exert its anti-inflammatory effects locally (in the GI tract) rather than systemically. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (catalyzes the formation of prostaglandin precursors from arachidonic acid), and through the lipoxygenase pathways (catalyzes the formation of leukotrienes and hydroxyeicosatetraenoic acids from arachidonic acid and its metabolites), is increased in patients with chronic inflammatory bowel disease. Therefore, it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon through both the inhibition of cyclooxygenase and lipoxygenase.
n3:packager
n10:271B51C4-363D-11E5-9242-09173F13E4C5 n10:271B51C5-363D-11E5-9242-09173F13E4C5 n10:271B51C3-363D-11E5-9242-09173F13E4C5 n10:271B51C8-363D-11E5-9242-09173F13E4C5 n10:271B51C9-363D-11E5-9242-09173F13E4C5 n10:271B51C6-363D-11E5-9242-09173F13E4C5 n10:271B51C7-363D-11E5-9242-09173F13E4C5
n3:patent
n11:7452872
n3:routeOfElimination
The products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-ß-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces. Following single-dose administration of 2.25 g COLAZAL (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.20%, 0.22% and 10.2%, respectively.
n3:synonym
(e)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid Balsalazido (e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid Balsalazidum Balsalazida 5-[4-(2-Carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
n3:toxicity
A single oral dose of balsalazide disodium at 5 grams/kg or 4-aminobenzoyl-(beta)-alanine, a metabolite of balsalazide disodium, at 1 gram/kg was non-lethal in mice and rats. No symptoms of acute toxicity were seen at these doses.
n3:proteinBinding
≥99%
n3:salt
n3:synthesisReference
Eckardt C. G. Wolf, Nageib Mohamed, Bhaskar Reddy Guntoori, "Safe process for the preparation of balsalazide." U.S. Patent US07271253, issued September 18, 2007.
n5:hasConcept
n6:M0116205
foaf:page
n8:balsalazide.htm n9:col1560.shtml n15:balsalazide.html
n3:IUPAC-Name
n4:271B51D6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B51DC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B51DB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B51D8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B51D9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B51DA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B51D4-363D-11E5-9242-09173F13E4C5 n4:271B51EC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B51D5-363D-11E5-9242-09173F13E4C5 n4:271B51ED-363D-11E5-9242-09173F13E4C5 n4:271B51D2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B51D3-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:A07EC04
n3:H-Bond-Acceptor-Count
n4:271B51E2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B51E3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B51DD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B51DE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B51E0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B51DF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B51E1-363D-11E5-9242-09173F13E4C5
n3:absorption
Low and variable, intact balsalazide is poorly absorbed systemically.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
80573-04-2
n3:category
n3:containedIn
n12:271B51CF-363D-11E5-9242-09173F13E4C5 n12:271B51CE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B51E8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B51EA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B51EB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B51E7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B51E6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B51E9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B51D7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B51E4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B51E5-363D-11E5-9242-09173F13E4C5